查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961203

缺血性心臟疾病治疗市场－全球产业规模、份额、趋势、机会、预测：依疾病类别、药物类别、地区和竞争格局划分，2021-2031年

Ischemic Heart Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Class, By Drug Class, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球缺血性心臟疾病(IHD) 治疗市场预计将从 2025 年的 62.3 亿美元成长到 2031 年的 79.8 亿美元，复合年增长率为 4.21%。

这些药物对于治疗心肌供血受限的疾病至关重要，例如心肌梗塞和心绞痛。市场成长的主要驱动因素是全球人口老化以及文明病相关合併症（包括肥胖和糖尿病）的日益普遍，这些疾病都需要长期药物治疗。根据美国心臟学会 (ACC) 2023 年的数据，缺血性心臟疾病影响着全球约 2.4 亿人，这使得国际市场对有效治疗性介入的需求持续迫切。

市场概览
预测期 2027-2031
市场规模：2025年 62.3亿美元
市场规模：2031年 79.8亿美元
复合年增长率：2026-2031年 4.21%
成长最快的细分市场 心绞痛
最大的市场 北美洲

阻碍市场扩张的一大障碍是重磅药物专利到期。这使得价格低廉的学名药得以进入市场。这种「专利悬崖」会大幅减少药物研发公司的收入来源，并迫使它们承担高昂的研发成本才能推出新药。此外，严格的监管流程和进行临床试验所需的大量资金投入，也使新参与企业的商业化过程更加复杂。

市场驱动因素

与生活方式相关的风险因素日益增多，是推动市场成长的主要动力。现代久坐的生活方式和环境因素加剧了心血管疾病的易感性。代谢紊乱，尤其是肥胖，会加速动脉粥状硬化的进展，因此医疗保健提供者需要开立药物进行预防和治疗。根据美国心臟协会于2024年1月发布的《2024年心臟病和中风统计更新》，肥胖的流行显着增加了心血管风险，约42%的美国成年人被归类为肥胖。这种盛行率与缺血事件的发生率直接相关，因此需要持续的药物治疗。此外，环境因素也加重了疾病负担。世界心臟联盟于2024年5月发布的报告显示，空气污染每年导致约190万人死于缺血性心臟疾病，凸显了除了传统的生活方式改变之外，还需要更多治疗性介入。

同时，新型药物疗法和生物製药的进步正在重塑治疗框架，改变市场格局，并扩大市场获利能力。Glucagon-Like Peptide-1(GLP-1) 受体促效剂在心血管领域的临床成功，标誌着治疗模式从传统的症状管理转变为主动风险降低的重大转变。根据诺和诺德公司于2024年3月发布的题为「Wegovy获FDA核准用于降低心血管风险」的新闻稿，治疗方法已被证实能显着降低已确诊心血管疾病成人患者发生主要心血管不利事件(MACE) 的风险达20%。这项监管突破不仅将拓展治疗选择，还将刺激製药公司投资开发针对代谢和缺血通路的多方面治疗方法，使更多患者群体受益。

市场挑战

重磅药物专利到期对全球缺血性心臟疾病（IHD）治疗市场的收入成长构成重大阻碍。一旦关键药物的独家销售权到期，市场将立即被生物等学名药充斥。这些竞争产品通常比品牌药便宜得多，并迅速侵蚀原厂药的市场份额。因此，儘管由于疾病的高发病率，处方量持续增长，但随着销售转向这些更具成本效益的替代药物，整体市场价值面临下行压力。

医疗保健系统正积极推广学名药以遏制医疗成本飙升，而由此带来的沉重财政负担进一步加剧了这一趋势。现有药物的高价定价模式难以为继，迫使製药公司依赖高风险的创新来维持盈利。根据美国心臟协会预测，到2050年，美国与心血管疾病相关的直接和间接总成本预计将增加两倍，达到约1.8兆美元（截至2024年）。日益增长的经济负担凸显了关键的市场动态：支付方优先考虑削减开支，这加剧了专利到期带来的影响，并限制了品牌缺血性心臟疾病治疗药物的获利能力。

市场趋势

随着对标准他汀类药物治疗无效的高风险患者越来越重视积极的降脂治疗，PCSK9抑制剂和生物目标的快速普及正在重塑市场格局。这一趋势的特征是siRNA疗法和单株抗体的应用日益广泛，它们能够以更少的剂量强效且持久地降低低密度脂蛋白（LDL）水平。因此，随着医疗系统将缺血性疾病的二级预防工具列为优先事项，製药开发商从这些先进的注射剂中获得了显着的收入成长。根据诺华公司于2024年10月发布的2024年第三季财报，其siRNA疗法RecVio的季度销售额为1.98亿美元，年增119%，凸显了这些标靶治疗的快速市场渗透。

同时，精准医疗的引进正在推动新型疗法的研发，以降低由基因决定的心血管风险，特别是高脂蛋白（α）水平。与传统的胆固醇管理不同，这种方法利用基因谱分析来识别具有传统药物无法解决的遗传易感性的患者，从而促进了RNA干扰疗法的研发。基因静默剂的最新进展也支持了这种向个人化医疗的转变，这些药物能够有效降低致病性脂蛋白的浓度。根据Silence Therapeutics公司于2024年11月发布的题为「Silence Therapeutics公布Zerlasiran最新二期临床试验数据」的新闻稿，在临床实验药物zerlasiran在36週内使已确诊心血管疾病患者的平均脂蛋白（α）水平降低了80%以上，证明了精准医疗方法的有效性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球缺血性心臟疾病（IHD）治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 疾病分类（心绞痛、心肌梗塞）
    • 药物分类（血脂异常症治疗药物、钙通道阻断剂、 β阻断剂、ACE抑制剂、ARB类药物、血管扩张剂、抗血栓药物）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美缺血性心臟疾病（IHD）治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲缺血性心臟疾病（IHD）治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区缺血性心臟疾病（IHD）治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲缺血性心臟疾病（IHD）治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲缺血性心臟疾病（IHD）治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球缺血性心臟疾病（IHD）治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20007

The Global Ischemic Heart Disease (IHD) Drugs Market is projected to expand from a valuation of USD 6.23 Billion in 2025 to USD 7.98 Billion by 2031, progressing at a compound annual growth rate (CAGR) of 4.21%. These pharmaceutical agents are essential for managing conditions defined by restricted blood supply to the heart muscle, such as myocardial infarction and angina pectoris. The market's upward trajectory is fundamentally underpinned by an aging global population and the increasing prevalence of lifestyle-related comorbidities, including obesity and diabetes, which necessitate long-term pharmacological management. Data from the American College of Cardiology in 2023 indicates that ischemic heart disease affects approximately 240 million people globally, creating an urgent and sustained demand for effective therapeutic interventions across international markets.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.23 Billion
Market Size 2031USD 7.98 Billion
CAGR 2026-20314.21%
Fastest Growing SegmentAngina Pectoris
Largest MarketNorth America

A significant barrier potentially hindering market expansion is the expiration of patents for major blockbuster therapies, which allows for the entry of cost-effective generic competitors. This "patent cliff" severely diminishes revenue streams for originator pharmaceutical companies, compelling them to navigate high development costs to introduce novel drugs. Furthermore, the commercialization process for new market entrants is complicated by stringent regulatory pathways and the immense financial investment required to conduct clinical trials.

Market Driver

The escalation of lifestyle-related risk factors serves as a primary engine for market growth, as modern sedentary behaviors and environmental conditions worsen cardiovascular vulnerabilities. Metabolic disorders, particularly obesity, accelerate the progression of atherosclerosis, compelling healthcare providers to prescribe preventative and management pharmacotherapies. According to the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024, the obesity epidemic significantly contributes to cardiovascular risk, with nearly 42% of the U.S. adult population classified as obese. This prevalence directly correlates with the incidence of ischemic events, necessitating sustained drug regimens. Additionally, environmental factors contribute to the disease burden; the World Heart Federation reported in May 2024 that ambient air pollution caused approximately 1.9 million deaths specifically from ischemic heart disease in a single year, highlighting the expanding need for therapeutic interventions beyond traditional lifestyle modifications.

Simultaneously, advancements in novel drug therapies and biologics are redefining the treatment landscape and expanding the market's revenue potential. The recent clinical success of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular applications marks a significant evolution from traditional symptom management to proactive risk reduction. According to a March 2024 press release by Novo Nordisk titled "Wegovy receives FDA approval for cardiovascular risk reduction," the treatment demonstrated a statistically significant 20% reduction in the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease. This regulatory milestone not only broadens the therapeutic arsenal but also incentivizes pharmaceutical investment in developing multi-modal treatments that address both metabolic and ischemic pathways, thereby capturing a larger share of the patient population.

Market Challenge

The expiration of patents for major blockbuster therapies constitutes a formidable barrier to revenue growth within the Global Ischemic Heart Disease (IHD) Drugs Market. When exclusive marketing rights for leading pharmaceutical agents conclude, the market witnesses an immediate influx of bioequivalent generic formulations. These competitors are typically priced significantly lower than their branded counterparts, leading to a rapid erosion of market share for originator companies. Consequently, despite a sustained or increasing volume of prescriptions due to high disease prevalence, the overall monetary value of the market faces downward pressure as sales shift toward these cost-effective alternatives.

This trend is further exacerbated by the intense financial strain on healthcare systems, which aggressively promote the adoption of generic medicines to mitigate soaring healthcare expenditures. The inability to maintain premium pricing models for established drugs forces pharmaceutical developers to rely heavily on new, high-risk innovations to sustain profitability. According to the American Heart Association, in 2024, the total direct and indirect costs related to cardiovascular disease in the United States were projected to triple to approximately $1.8 trillion by 2050. This escalating economic burden underscores the critical market dynamic where payers prioritize reduced spending, thereby amplifying the impact of patent cliffs and restricting the revenue potential for branded ischemic heart disease therapies.

Market Trends

The accelerated adoption of PCSK9 inhibitors and targeted biologics is reshaping the market by addressing the critical need for aggressive lipid lowering in high-risk patients unresponsive to standard statin regimens. This trend is characterized by the increasing uptake of small interfering RNA therapies and monoclonal antibodies that offer potent, sustained low-density lipoprotein reduction with infrequent dosing schedules. Consequently, pharmaceutical developers are witnessing substantial revenue growth from these advanced injectables as healthcare systems prioritize secondary prevention tools for ischemic conditions. According to Novartis's "Q3 2024 Results" from October 2024, the company's siRNA therapy, Leqvio, recorded sales of $198 million for the quarter, representing a 119% increase compared to the previous year, highlighting the rapid market penetration of these targeted interventions.

Simultaneously, the implementation of precision medicine is driving the development of novel therapeutics designed to mitigate genetically determined cardiovascular risks, specifically elevated Lipoprotein(a). Unlike traditional cholesterol management, this approach utilizes genetic profiling to identify patients with inherited vulnerabilities that remain unaddressed by conventional drugs, fostering a new pipeline of RNA-interference therapies. This shift towards personalized care is evidenced by recent clinical advancements in gene-silencing agents that effectively reduce pathogenic lipoprotein concentrations. According to a November 2024 press release by Silence Therapeutics titled "Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data," the investigational drug zerlasiran demonstrated a time-averaged reduction in Lipoprotein(a) of more than 80% over 36 weeks in patients with established cardiovascular disease, validating the efficacy of these precision modalities.

Key Market Players

  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Ischemic Heart Disease (IHD) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ischemic Heart Disease (IHD) Drugs Market, By Disease Class

  • Angina Pectoris
  • Myocardial Infarction

Ischemic Heart Disease (IHD) Drugs Market, By Drug Class

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents

Ischemic Heart Disease (IHD) Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ischemic Heart Disease (IHD) Drugs Market.

Available Customizations:

Global Ischemic Heart Disease (IHD) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Class (Angina Pectoris, Myocardial Infarction)
    • 5.2.2. By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Class
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Class
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Class
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Class
        • 6.3.3.2.2. By Drug Class

7. Europe Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Class
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Class
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Class
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Class
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Class
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Class
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Class
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Class
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Class
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Class
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Class
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Class
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Class
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Class
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Class
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Class
        • 9.3.3.2.2. By Drug Class

10. South America Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Class
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Class
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Class
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Class
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ischemic Heart Disease (IHD) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Novartis International AG
  • 15.4. Pfizer, Inc.
  • 15.5. Sanofi S.A.
  • 15.6. Actelion Pharmaceuticals Ltd.
  • 15.7. Baxter International Inc.
  • 15.8. Boehringer Ingelheim International GmbH
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer